Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business's STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders.
Future Labs is part of Apimeds' ai² innovation platform, connecting university students with real-world biopharmaceutical strategy and business development projects. Through this partnership, student teams will work closely with Apimeds mentors to identify and evaluate opportunities to advance development projects previously abandoned by industry.
"We're excited to welcome The University of Alabama and their STEM Path to the MBA students to the Future Labs program," said Erik Emerson, CEO of Apimeds. "UA will be the first of a select group of academic institutions we partner with to identify opportunities to improve patient care by reexamining promising projects. Drug development is complex, expensive, and time-consuming, which means many therapies with true potential never reach patients. Future Labs is designed to function as a discovery engine for products and future leaders – we look forward to working with University of Alabama and the students – Roll Tide – until you encounter #goducks."
Students will gain hands-on experience in market analysis, FDA regulations, clinical development requirements, competitive positioning, intellectual property considerations, and commercialization planning—skills that extend far beyond the classroom. Top-performing teams at each participating institution will be eligible for paid internships or consulting opportunities with Apimeds, providing a direct pathway into the industry.
"We see this program as a way to uncover development opportunities while also giving students a practical look at the business side of biopharma," said Brian Peters, SVP of the ai² Division at Apimeds Pharmaceuticals.
Rob Morgan, Ph.D., Director of the STEM Path and CREATE Path to the MBA programs at The University of Alabama, added: "Our students will gain unique experience contributing to the success of a biopharma company. This program provides a one-of-a-kind opportunity to bring the business of biotechnology to a new generation of leaders."
The partnership underscores Apimeds' commitment to fostering innovation, building industry–academic alliances, and developing the next generation of biotech leaders.
About Apimeds Pharmaceuticals
Apimeds Pharmaceuticals (NYSE:APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. The company's lead product candidate, Apitox, is in late-stage clinical development for osteoarthritis of the knee. For more information visit www.apimedsus.com. Information on the Apimeds' website does not constitute a part of and is not incorporated by reference into this press release.
About Culverhouse College of Business and the STEM Path to the MBA Program
Established in 1919 by Lee Bidgood and currently led by Dean Kay Palan, the Culverhouse College of Business at The University of Alabama is a top-ranked leader in business education, offering bachelor's, master's, and doctoral degrees and has been accredited by AACSB since 1929.
Culverhouse launched the STEM Path to the MBA program in 2011, providing students from technical and scientific disciplines with unique exposure to business education throughout their undergraduate studies, culminating in the earning of an MBA with one additional year of study.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "anticipate", "believe", "expect", "plan" and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds' actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds' results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds' ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds' filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on April 15, 2025 (as amended on May 2, 2025).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250825099354/en/
Media:
Brian Peters
Apimeds Pharmaceuticals
919-602-6557